Abstract
SEK1 (MKK4/JNKK) is a mitogen-activated protein kinase activator that has been shown to participate in vitro in two stress-activated cascades terminating with the SAPK and p38 kinases. To define the role of SEK1 in vivo, we studied stress-induced signaling in SEK1−/− embryonic stem and fibroblast cells and evaluated the phenotype of SEK1−/− mouse embryos during development. Studies of SEK1−/− embryonic stem cells demonstrated defects in stimulated SAPK phosphorylation but not in the phosphorylation of p38 kinase. In contrast, SEK1−/− fibroblasts exhibited defects in both SAPK and p38 phosphorylation, demonstrating that crosstalk exists between the stress-activated cascades. Tumor necrosis factor α and interleukin 1 stimulation of both stress-activated cascades are severely affected in the SEK1−/− fibroblast cells. SEK1 deficiency leads to embryonic lethality after embryonic day 12.5 and is associated with abnormal liver development. This phenotype is similar to c-jun null mouse embryos and suggests that SEK1 is required for phosphorylation and activation of c-jun during the organo-genesis of the liver.
Three vertebrate mitogen-activated protein kinase (MAPK) cascades have been shown to regulate signal transduction necessary for the development and function of many tissues (1–3). The stress-activated kinase cascade involving MEKK, SEK1, and SAPK leads to the phosphorylation of c-jun and is activated by stress stimuli such as interleukin 1 (IL-1), tumor necrosis factor α (TNFα), heat shock, UV irradiation, and protein synthesis inhibition. The p38 MAPK cascade is activated by similar stimuli. The upstream kinases MKK3 and MKK6 function to activate p38(4–7). The MAPK SEK1 (also called MKK4 or JNKK) is capable of phosphorylating and activating SAPK in vitro. Furthermore, kinase inactive mutants of SEK1 specifically prevent SAPK activation by stress stimuli (4). SEK1 also has been shown to phosphorylate and activate p38 MAPK in vitro (4), suggesting that SEK1 may participate in the regulation of two independent MAPK cascades.
Two recent reports have evaluated the function of SEK1 in murine embryonic stem (ES) cells (8, 9). These targeted gene disruption experiments demonstrated a significant defect in SAPK activity in response to stress signals such as anisomycin and heat shock. The activation of SAPK in response to UV irradiation was affected less dramatically in these SEK1-deficient ES cells, suggesting the existence of another kinase that activates SAPK. A candidate could be the recently cloned SEK1 family member MKK7 (10), which has been shown to specifically activate SAPK but not p38. Although these reports show that the activation of SAPK is affected in SEK1−/− ES cells, there are no defects seen in p38 kinase activity, implying that SEK1 only regulates the SAPK cascade in vivo and that the activation of p38 by SEK1 is an in vitro phenomenon.
These reports do not address the role of SEK1 in TNFα and IL-1 signaling. ES cells do not express receptors for TNFα and IL-1. To evaluate this, we generated SEK1−/− embryonic fibroblast lines and studied the response of these cells after treatment with different stimuli. Surprisingly, a significant defect in IL-1 and TNFα stimulation of both SAPK and p38 phosphorylation was detected and demonstrated that crosstalk between the SAPK and p38 MAPK cascades can occur through SEK1. The difference between these results obtained in SEK1−/− fibroblasts with the studies of SEK1−/− ES cells suggests that the signal-dependent activation of the cascades is distinct in different cell types. As reported (8, 9), SEK1 deficiency leads to an embryonic lethality some time before embryonic day (E) 14.5, but no information exists as to the function of SEK1 in development before this time or to the cause of death. Our analysis of the SEK1−/− mouse embryos demonstrates abnormal liver formation and hemorrhage. The similarity of this phenotype with that of c-jun-deficient embryos suggests that the stress-activated MAPK cascades lead to c-jun activation, which may be involved in normal liver development in vivo.
MATERIALS AND METHODS
Targeted Disruption of the SEK1 Gene.
W9.5 ES cells were used for homologous recombination as described (11, 12) by using pGKneo/TK for construction of the targeting vector. The targeting vector was produced by insertion of a 6-kb BglII fragment into the BamHI site of pGKneo/TK followed by insertion of a 1-kb EcoRI fragment into the PmeI site of the resulting vector. Initial selection of targeted ES cells was carried out first in 175 mg/ml G418 and later in 2 mg/ml G418 to obtain SEK1−/− cells.
ES Cell Culture.
The ES cell lines were adapted by passage on gelatin plates and cultured in DMEM (Gibco/BRL) containing 15% fetal calf serum (HyClone), 2 mM glutamine (Gibco/BRL), 1× nonessential amino acids (Gibco/BRL), 0.1 mM β-mercaptoethanol (Sigma), 100 units/ml penicillin–streptomycin (Gibco/BRL), and 1,000 units/ml lymphocyte inhibitory factor (Gibco/BRL) at 37°C and in 5% CO2.
Mouse Embryonic Fibroblast (MEF) Cultures.
E13.5 embryos were isolated from an outbred mouse strain, from wild-type129Sv mice, or from chimeric embryos created by injection of nontransgenic blastocysts with SEK1−/− ES cells. Wild-type and SEK1−/− embryonic fibroblasts were cultured in 10% fetal bovine serum (HyClone), 2 mM glutamine (Gibco/BRL), and 1 mM nonessential amino acids (Gibco/BRL). SEK1−/− embryonic fibroblasts were maintained in 400 μg/ml G418 and were passaged at least twice to eliminate wild-type fibroblasts.
Western Blot Analysis.
Immunoblot analysis of cell lysates was performed by probing with polyclonal antibodies to SAPK/JNK, phosphorylated SAPK/JNK (Thr 183/Tyr 185) (New England Biolabs), p38 and phosphorylated p38 (New England Biolabs), MKK3 [Santa Cruz Biotechnology, MEK-3 (C-19)] and phosphorylated MKK3/MKK6 (Ser189/207) (New England Biolabs), and SEK1 (Santa Cruz Biotechnology). Immune complexes were detected by enhanced chemiluminescence (Amersham).
Immunohistochemistry and in Situ Hybridization.
Specimens were fixed with 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.2) at 4°C overnight, were dehydrated through a graded alcohol series, and were embedded in paraffin. Sections of 4 μm were prepared and stained with Harris hematoxylin and eosin according to standard procedures.
In Situ hybridization of specimens were carried out as reported (13). Apoptosis assays were carried out by using an ApopTag kit (Oncor) as recommended by the manufacturer. For counting cells stained with the cytokeratin antibody or by ApopTag, three high power fields (×63) of two different individual animals were evaluated.
RESULTS AND DISCUSSION
To generate a targeted mutation of the SEK1 locus, we disrupted two exons encoding part of the catalytic domain (Fig. 1). The modification introduces a frame shift that causes a deletion mutation. This modified gene should produce only a truncated SEK1 protein that would not function. Several independent heterozygous (SEK1+/−) ES lines were generated. Multiple distinct SEK1−/− ES cell lines also were isolated by culture in increased G418 concentration (14) (Fig. 1B) as well as by retargeting the second allele (data not shown). Western blot analysis demonstrated that SEK1 protein was not detected in these ES cell lines (Fig. 1C). Compared with wild-type ES cells, heterozygous lines expressed about one-half the amount of SEK1 protein.
To examine the effect of SEK1 gene disruption on the phosphorylation and activation of SAPK and p38 in ES cells, the following experiments were performed. Wild-type and SEK1−/− ES cells were treated with anisomycin, heat shock, and UV irradiation. SEK1−/− ES cells treated with anisomycin or heat shock exhibited no SAPK phosphorylation compared with wild-type cells, as shown by western blot analysis with a phospho-SAPK antibody (Fig. 2 a and b). No difference in p38 phosphorylation was seen in ES cells. Thus, SEK1 has a specific role in the SAPK signal transduction pathway in response to these stimuli whereas the p38 signaling cascade in ES cells is not dependent on SEK1 activity. In contrast, UV irradiation of the SEK1−/− ES cell lines led to activation of SAPK phosphorylation, but the activation of SAPK was lower than in wild-type ES cell lines (Fig. 2b), supporting a model where alternative pathways exist that lead to the phosphorylation of SAP kinases. Another MAPK activator, MKK7, has been described recently (10) and could suffice in this role. To demonstrate that c-jun activity is affected by the lack of SAPK phosphorylation in the SEK1−/− cells, we used a c-jun dependent reporter system (PathDetect, Stratagene). The PathDetect in vivo reporter system includes the fusion activator plasmids that consist of the DNA binding domain of the yeast GAL4 fusion activator and the activation domain of the c-jun transcription factor. Stimulation of cells with anisomycin or by MEKK transfection led to activation of the reporter construct in wild-type ES cells; in contrast, activity was stimulated poorly in the SEK1−/− cells (data not shown). These results are similar to those reported for SEK1−/− ES cells (8, 9).
Because ES cells do not express the receptors for IL-1 or TNFα, the role of cytokine signaling was investigated in SEK1-deficient MEFs. Western blot analysis confirmed that these lines were deficient in SEK1 protein (Fig. 1D). Wild-type fibroblast cells responded to IL-1 or TNFα by increased phosphorylation of SAPK (Fig. 2c). In contrast, SEK1−/− fibroblasts were low or undetectable in SAPK phosphorylation in response to IL-1 or TNFα . SAPK phosphorylation also was low or undetectable in response to anisomycin or sorbitol in these cells (Fig. 2d). Surprisingly, p38 phosphorylation also is reduced in response to IL-1, TNFα, and anisomycin (Fig. 2 c and d), whereas sorbitol-stimulation leads to an equivalent level of p38 phosphorylation in wild-type and SEK1−/− fibroblast cells. Because SEK1 has been shown to phosphorylate p38 in vitro (15), our data supports a model in which crosstalk exists between the two stress-activated cascades. As MKK3/6 have been shown to be the upstream activators of p38, we examined the effect of MKK3/6 activation by these cytokines in the SEK1 deficient embryonic fibroblasts. IL-1 does not stimulate MKK3/6 phosphorylation in the absence of SEK1 (Fig. 2e) whereas sorbitol leads to MKK3/6 phosphorylation. This finding, taken together with the lack of SAPK phosphorylation in IL-1 or sorbitol treatment of SEK1 deficient fibroblasts, demonstrates that SEK1 regulates MKK3/6 activation independent of SAPK activity. This could occur directly through a protein interaction between SEK1 and MKK3/6 or indirectly by SEK1 regulation of upstream activators of MKK3/6. Alternatively, it is possible that there is an indirect effect of targeting SEK1. For example, the fibroblasts that are SEK1 deficient grow more slowly compared with the wild-type cells, perhaps supporting prior evidence for effects of the stress-activated cascades on the cell cycle (16–18). These results demonstrate that SEK1 can affect p38 activity in vivo and that crosstalk between the SAPK and p38 cascades occurs. The differences in p38 phosphorylation in SEK1−/− ES and fibroblast cells suggests that the stimulation and crossregulation of these two stress-activated cascades is cell-type dependent.
To determine whether SEK1 is required for normal development, SEK1+/− ES cells were injected into host blastocysts, and chimeric mice were derived. Through matings, heterozygous mice were obtained, and these mice were bred to obtain SEK1 null animals. Deficiency of SEK1 is embryonically lethal. No live births were found in >150 offspring. Yang et al. (8) also noted an embryonic lethality with no SEK1−/− animals surviving beyond E14.5 (8). In our studies, timed matings of heterozygotes produced viable SEK1−/− embryos at E12.5. These embryos exhibited a severe phenotype that included hemorrhage in the region of the liver (Fig. 3a). Examination of SEK1−/− embryos from E11.5–12.5 demonstrated that the liver bud forms but is considerably reduced in size compared with wild-type embryos. Livers from SEK1−/− embryos exhibit abnormal histology, including enlarged sinuses (large arrows), and many embryonic livers have two small lobes (small arrows). To further examine the embryonic liver, tissue sections were stained with various antibodies such as cytokeratin and Factor VIII (Dako) to look at the hepatocytes and the liver architecture in general. The liver abnormalities appeared to be caused by a decrease in hepatocyte number. Cytokeratin staining (19) at E11.5 demonstrated a reduced number of hepatocytes per embryo in SEK1−/− animals (Fig. 3b Top). The liver size increased between E11.5 to E12.5 in the SEK1−/− embryos, almost reaching an equivalent size as the wild-type liver. However, the number of hepatocytes per high power field in the liver of SEK1−/− embryos was lower than in the wild-type controls (see Fig. 3 legend). The sinuses of the liver continued to enlarge, and hemorrhage occurred into the cavity (Fig. 3a). To examine whether increased hepatocyte death was contributing to the liver degeneration, apoptosis assays were performed on the embryonic liver sections. There was almost a 2-fold increase in the number of apoptotic hepatocytes in the SEK1−/− livers (Fig. 3b Bottom and figure legend). Increased apoptosis could contribute to the liver abnormality; however, a 2-fold increase may not be sufficient to explain the cause of death. Although the exact cause of embryo death is unknown, the pale appearance and massive bleeding suggest that the embryos may die of anemia. Although stress-induced MAPK cascades are activated by hematopoietic cytokines (20, 21), yolk sac progenitor studies from E10.5 SEK1−/− embryos exhibit normal hematopoiesis (S.G. and L.I.Z., unpublished material). In situ hybridization studies demonstrated only slightly lower expression of liver-specific markers, transthyretin (Fig. 3c) (22), and α -fetoprotein (data not shown) (23) in the SEK1−/− liver bud, suggesting that there was no obvious problem with differentiation. Factor VIII staining of tissue sections demonstrated that SEK1−/− sinusoids frequently were lined with loose endothelial cells (Fig. 3d Top). Because endothelial cells in other tissues appeared grossly normal (Fig. 3d Bottom), it is likely that a primary defect in SEK1−/− livers is the hepatocyte number and architecture and not abnormalities in endothelial cells in general. To further define the defect in liver formation of SEK1−/− cells, we performed chimeric analysis. SEK1−/− ES cells were injected into wild-type blastocysts, and DNA prepared from isolated tissues was subjected to Southern blot analysis. The only tissue that consistently shows extremely low or no contribution from the SEK1−/− ES cells was the liver (Fig. 3e). Histological analysis of a liver from one high-level chimera demonstrated abnormal liver architecture, including hepatocyte hypoplasia and nuclear fragmentation of hepatocytes characteristic of apoptosis (Fig. 3f). These data suggest that SEK1 is cell autonomous for hepatocyte growth.
The phenotype of the SEK1-deficient mouse is strikingly similar to the c-jun-deficient mouse (24–26). It is possible that other genes important in liver development such as relA (27) and Hlx (28) may be targets of the SAPK or p38 cascades and thus may account for the defect in liver formation. As c-jun has been proposed to be a target of the SEK1/SAPK cascade, it is likely that the kinase cascade regulates c-jun phosphorylation during hepatogenesis. SAPK has been shown to be activated in liver extracts by metabolic stress (29), and SAPK signaling has been postulated to control fetal hepatocyte proliferation (30). Partial hepatectomy and subsequent liver regeneration also lead to SAPK activation and c-jun phosphorylation (31). p38 also has been shown to be activated in regenerating adult rat hepatocytes (32). In addition, p38 has been shown to activate transcription factors such as MEF2 (33), which may ultimately regulate tissue differentiation and proliferation. Stimulation of the met oncogene, which is the receptor for hepatocyte growth factor, or the met-related STK/RON receptor, which is the receptor for macrophage stimulating protein, recently has been shown to activate the SAPK pathway (34, 35). Furthermore, defects in mice deficient in hepatocyte growth factor or c-met (11, 12) are similar to defects in mice deficient in SEK1 or c-jun, perhaps indicating the existence of a ligand-stimulated cascade of events responsible for liver formation in vivo. Our studies of the SEK1−/− ES cells and embryos formally demonstrate that SEK1 is required for normal liver development in vivo and suggests a model in which the SEK1/SAPK kinase cascade is required for c-jun phosphorylation during embryogenesis.
Acknowledgments
We thank A. Perez-Atayde, M. Donovan, E. Matczak, and J. Edwards of the Pathology Department at Children’s Hospital for the assistance with the histology. We thank K. Zaret and E. Wagner for their helpful discussions. We thank S. Orkin, B. Mayer, and B. Morgan for reviewing the manuscript. We thank D. Giarla for excellent help in preparing the illustrations and manuscript. L.I.Z. is an Associate Investigator with the Howard Hughes Medical Institute. This work was supported by National Institutes of Health Grant 2 PO1 HL32262.
Footnotes
This paper was submitted directly (Track II) to the Proceedings Office.
Abbreviations: MAPK, mitogen-activated protein kinase; ES, embryonic stem; TNFα, tumor necrosis factor α; IL-1, interleukin 1; E, embryonic day; MEF, mouse embryonic fibroblast.
References
- 1.Su B, Karin M. Curr Opin Immunol. 1996;8:402–411. doi: 10.1016/s0952-7915(96)80131-2. [DOI] [PubMed] [Google Scholar]
- 2.Treisman R. Curr Opin Cell Biol. 1996;8:205–215. doi: 10.1016/s0955-0674(96)80067-6. [DOI] [PubMed] [Google Scholar]
- 3.Marshall C J. Cell. 1995;80:179–185. doi: 10.1016/0092-8674(95)90401-8. [DOI] [PubMed] [Google Scholar]
- 4.Sanchez I, Hughes R T, Mayers B J, Yee K, Woodgett J R, Avruch J, Kyrlakis J M, Zon L I. Nature (London) (London) 1994;372:794–798. doi: 10.1038/372794a0. [DOI] [PubMed] [Google Scholar]
- 5.Yan M, Dai T, Deak J C, Kyriakis J M, Zon L I, Woodgett J R, Templeton D J. Nature (London) (London) 1994;372:798–800. doi: 10.1038/372798a0. [DOI] [PubMed] [Google Scholar]
- 6.Derijard B, Hibi M, Wu I H, Barrett T, Su B, Deng T, Karin M, Davis R J. Cell. 1994;76:1025–1037. doi: 10.1016/0092-8674(94)90380-8. [DOI] [PubMed] [Google Scholar]
- 7.Kyriakis J M, Banerjee P, Nikolakaki E, Dai T, Rubie E A, Avruch J, Woodgett J R. Nature (London) (London) 1994;369:156–160. doi: 10.1038/369156a0. [DOI] [PubMed] [Google Scholar]
- 8.Yang D, Tournier C, Wysk M, Lu H-T, Xu J, Davis R J, Flavell R A. Proc Natl Acad Sci USA. 1997;94:3004–3009. doi: 10.1073/pnas.94.7.3004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Nishina H, Fischer K D, Radvanyi L, Shahinian A, Hakem R, Rubie E A, Bernstein A, Mak T W, Woodgett J R, Penninger J M. Nature (London) 1997;385:350–353. doi: 10.1038/385350a0. [DOI] [PubMed] [Google Scholar]
- 10.Tournier C, Whitmarsh A J, Cavanagh J, Barrett T, Davis R J. Proc Natl Acad Sci USA. 1997;94:7337–7342. doi: 10.1073/pnas.94.14.7337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardl E, Birchmeier C. Nature (London) 1995;373:699–702. doi: 10.1038/373699a0. [DOI] [PubMed] [Google Scholar]
- 12.Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N. Nature (London) 1995;373:702–705. doi: 10.1038/373702a0. [DOI] [PubMed] [Google Scholar]
- 13.Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. J Clin Invest. 1993;92:2814–2820. doi: 10.1172/JCI116901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Mortensen R M, Conner D A, Chao S, Geisterfer-Lowrance A A T, Seidman J G. Mol Cell Biol. 1992;12:2391–2395. doi: 10.1128/mcb.12.5.2391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Dérijard B, Raingeaud J, Barrett T, Wu I-H, Han J, Ulevitch R J, Davis R J. Science. 1995;267:682–685. doi: 10.1126/science.7839144. [DOI] [PubMed] [Google Scholar]
- 16.Watanabe G, Howe A, Lee R J, Albanese C, Shu I W, Karnezis A N, Zon L, Kyriakis J, Rundell K, Pestell R G. Proc Natl Acad Sci USA. 1996;93:12861–12866. doi: 10.1073/pnas.93.23.12861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lavoie J N, L’Allemain G, Brunet A, Muller R, Pouyssegur J. J Biol Chem. 1996;271:20608–20616. doi: 10.1074/jbc.271.34.20608. [DOI] [PubMed] [Google Scholar]
- 18.Molnar A, Theodoras A M, Zon L I, Kyriakis J M. J Biol Chem. 1997;272:13229–13235. doi: 10.1074/jbc.272.20.13229. [DOI] [PubMed] [Google Scholar]
- 19.Zatloukal K, Denk H, Spurej G, Lackinger E, Preisegger K-H, Franke W W. Lab Invest. 1990;62:427–434. [PubMed] [Google Scholar]
- 20.Foltz I N, Lee C J, Young P R, Schrader J W. J Biol Chem. 1997;272:3296–3301. doi: 10.1074/jbc.272.6.3296. [DOI] [PubMed] [Google Scholar]
- 21.Foltz I N, Schrader J W. Blood. 1997;89:3092–3096. [PubMed] [Google Scholar]
- 22.Makeover A, Soprano D R, Wyatt M L, Goodman D S. Differentiation. 1989;40:17–25. doi: 10.1111/j.1432-0436.1989.tb00809.x. [DOI] [PubMed] [Google Scholar]
- 23.Van Den Hoff M J B, Vermeulen J L M, De Boer P A J, Lamers W H, Moorman A F M. Histochem J. 1994;26:20–31. [PubMed] [Google Scholar]
- 24.Hilberg F A, Aguzzi A, Howells N, Wagner E F. Nature (London) 1993;365:179–181. doi: 10.1038/365179a0. [DOI] [PubMed] [Google Scholar]
- 25.Johnson R S, van Lingen B, Papaioannou V E, Spiegelman B M. Genes Dev. 1993;7:1309–1317. doi: 10.1101/gad.7.7b.1309. [DOI] [PubMed] [Google Scholar]
- 26.Roffler-Tarlov S, Brown J J, Tarlov E, Stolarov J, Chapman D L, Alexiou M, Papaioannou V E. Development (Cambridge, UK) 1996;122:1–9. doi: 10.1242/dev.122.1.1. [DOI] [PubMed] [Google Scholar]
- 27.Beg A A, Sha W C, Bronson R T, Ghosh S, Baltimore D. Nature (London) 1995;376:167–170. doi: 10.1038/376167a0. [DOI] [PubMed] [Google Scholar]
- 28.Hentsch B, Lyons I, Li R, Hartley L, Lints T J, Adams J M, Harvey R P. Genes Dev. 1996;10:70–79. doi: 10.1101/gad.10.1.70. [DOI] [PubMed] [Google Scholar]
- 29.Mendelson K G, Contois L-R, Tevosian S G, Davis R J, Paulson K E. Proc Natl Acad Sci USA. 1996;93:12908–12913. doi: 10.1073/pnas.93.23.12908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Boylan J M, Gruppuso P A. Cell Growth Differ. 1996;7:1261–1269. [PubMed] [Google Scholar]
- 31.Westwick J K, Weitzel C, Leffert H L, Brenner D A. J Clin Invest. 1995;95:803–810. doi: 10.1172/JCI117730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Spector M S, Auer K L, Jarvis W D, Ishac E J N, Gao B, Kunos G, Dent P. Mol Cell Biol. 1997;17:3556–3565. doi: 10.1128/mcb.17.7.3556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. Nature (London) 1997;386:296–299. doi: 10.1038/386296a0. [DOI] [PubMed] [Google Scholar]
- 34.Iwama A, Yamaguchi N, Suda T. EMBO J. 1996;15:5866–5875. [PMC free article] [PubMed] [Google Scholar]
- 35.Rodrigues G A, Park M, Schlessinger J. EMBO J. 1997;16:2634–2645. doi: 10.1093/emboj/16.10.2634. [DOI] [PMC free article] [PubMed] [Google Scholar]